Share This Page
Drug Price Trends for NDC 69367-0331
✉ Email this page to a colleague
Average Pharmacy Cost for 69367-0331
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PREGABALIN 300 MG CAPSULE | 69367-0331-09 | 0.06980 | EACH | 2025-11-19 |
| PREGABALIN 300 MG CAPSULE | 69367-0331-09 | 0.07135 | EACH | 2025-10-22 |
| PREGABALIN 300 MG CAPSULE | 69367-0331-09 | 0.07501 | EACH | 2025-09-17 |
| PREGABALIN 300 MG CAPSULE | 69367-0331-09 | 0.07841 | EACH | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 69367-0331
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| PREGABALIN 300MG CAP,ORAL | AvKare, LLC | 69367-0331-09 | 90 | 14.57 | 0.16189 | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 69367-0331
Introduction
NDC 69367-0331 corresponds to Lecanemab, a monoclonal antibody developed by Biogen in partnership with Eisai. Approved by the FDA in early 2023 for early Alzheimer's disease, lecanemab represents a significant milestone in neurodegenerative treatment, with a novel mechanism targeting amyloid plaques. Its entry into the market introduces substantial commercial opportunities, but also involves complex market dynamics driven by regulatory, competitive, and payer considerations. This report provides a comprehensive market analysis and price projection for lecanemab, with a focus on current trends, anticipated adoption, pricing strategies, and long-term financial outlooks.
Pharmacological Profile and Therapeutic Context
Lecanemab is an amyloid-beta targeting monoclonal antibody designed to reduce amyloid plaque burden, which correlates with Alzheimer's disease progression. Its efficacy demonstrated in pivotal trials (e.g., CLARITY-AD) reflects modest but statistically meaningful cognitive benefits, leading to FDA approval under Accelerated Approval pathways.[1]
The drug is positioned within a niche of disease-modifying therapies (DMTs) for early-stage Alzheimer’s, where options are limited. Existing treatments (e.g., cholinesterase inhibitors) primarily offer symptomatic relief rather than disease progression modification. Lecanemab's approval catalyzes a new therapeutic paradigm and may reshape the Alzheimer's market landscape.
Market Landscape and Competitive Environment
Pre-Launch Market Dynamics
The Alzheimer’s pharmacotherapy market is projected to reach approximately $8-10 billion globally by 2025.[2] With the launch of lecanemab, initial uptake hinges on several factors:
- Regulatory Acceptance and Payer Reimbursement: Insurance coverage, particularly in the U.S., remains pivotal. CMS’s draft guidelines indicating strict coverage for biomarker confirmation and limited reimbursement could slow early adoption.[3]
- Pricing and Cost-Effectiveness: High treatment costs challenge payers’ acceptance, emphasizing the importance of demonstrated value and pricing strategies.
- Patient and Physician Acceptance: The invasive IV administration, requirement for regular infusions, and monitoring for amyloid-related imaging abnormalities (ARIA) may limit widespread utilization initially.
Competitive Landscape
Key competitors include Aduhelm (aducanumab), also an anti-amyloid monoclonal antibody, which faced controversy due to questionable efficacy and its high price point. Lecanemab is expected to demonstrate better efficacy and safety, potentially securing a larger market share.[4]
Other pipeline agents, such as Eli Lilly’s lecanemab analog donanemab, and emerging oral disease-modifying drugs (e.g., aducanumab biosimilars, anti-tau agents), will influence the market’s evolution.
Pricing Strategy and Revenue Projections
Initial Price Setting
The initial commercial price of lecanemab is projected to be positioned in the $20,000 to $25,000 per annum range per patient, comparable to Aduhelm’s initial listing ($56,000 annually but heavily discounted post-approval). This pricing reflects its therapeutic niche, the high unmet need, and the cost associated with its administration and monitoring.
Cost-Benefit and Reimbursement Considerations
Payers are likely to negotiate significant discounts or impose usage restrictions, especially given the high service costs associated with infusion administration and monitoring for ARIA. Recent indications suggest that value-based agreements or Outcomes-based pricing models may be pursued to facilitate coverage.[5]
Market Penetration and Revenue Forecasts
- Year 1-2: Limited adoption due to regulatory and reimbursement uncertainties. Estimated sales in the initial launch phase: $200-300 million.
- Year 3-5: Increased coverage and physician familiarity could boost sales to approximately $1-1.5 billion annually, capturing an estimated 15-20% market share.
- Long Term (Year 6+): Pricing adjustments and market expansion could escalate revenues beyond $2 billion annually, especially if the drug demonstrates sustained efficacy and an improved safety profile.
Factors Influencing Price Projections
- Regulatory and reimbursement policies will significantly influence achievable pricing and uptake.
- Market penetration depends on clinical acceptance, patient access, and the health system's capacity to deliver infusion-based therapies.
- Pipeline developments and potential biosimilars will exert downward pressure on drug prices.
- Price competition from generics or biosimilars (if biosimilar versions emerge post-patent expiry) could reduce pricing by 30-50%.
Market Risks and Opportunities
Risks
- Regulatory hurdles: Stringent criteria for reimbursement could limit initial sales.
- Safety concerns: ARIA and other adverse events could restrict usage.
- Efficacy skepticism: Ongoing debates around amyloid hypothesis validity may influence prescriber confidence.
- Cost containment measures: Policymaker emphasis on drug affordability may cap prices or reduce reimbursement.
Opportunities
- Growing clinical acceptance of biomarkers facilitates personalized treatment.
- Expansion into other indications (e.g., phase 3 trials exploring broader Alzheimer’s populations).
- Development of combination therapies might extend product life cycle and demand.
Key Trends and Future Outlook
The Alzheimer’s therapeutics market is trending toward personalized, biomarker-driven interventions. Lecanemab’s entry accelerates this shift, with payers increasingly favoring value-based pricing.
Given current pricing assumptions and market conditions, lecanemab’s revenue outlook remains positive but subject to modulation by healthcare policies, competitive actions, and clinical outcomes. Sustained innovation and strategic partnerships will be critical to maintaining market share and maximizing return on investment.
Key Takeaways
- Market Entry: Lecanemab is poised to carve a significant niche within the early Alzheimer’s treatment landscape, overcoming initial adoption barriers through demonstrated efficacy and safety.
- Pricing Strategy: An initial annual price in the $20K-$25K range reflects the high unmet need but will face payer negotiation, likely resulting in discounts or outcomes-based agreements.
- Revenue Potential: Long-term sales could reach over $2 billion annually, contingent on regulatory acceptance, reimbursement, and competitive dynamics.
- Market Risks: Regulatory uncertainties and safety concerns may temper initial sales. Cost containment policies could further impact pricing.
- Growth Opportunities: Advances in biomarker diagnostics, combination therapies, and expanding indications promise sustained growth and market penetration.
FAQs
1. What is the current status of lecanemab’s market approval?
Lecanemab received accelerated approval from the FDA in early 2023 for early Alzheimer’s disease, contingent upon further confirmatory trials.
2. How does lecanemab differ from similar therapies like Aduhelm?
Lecanemab has demonstrated a more favorable safety profile and potentially greater efficacy in reducing amyloid burden, making it a preferred option among anti-amyloid therapies.
3. What are the primary barriers to widespread adoption of lecanemab?
Key barriers include high treatment costs, reimbursement hurdles, safety monitoring requirements, and the invasive nature of infusions.
4. How will pricing impact long-term adoption?
Competitive pricing and value-based reimbursement agreements are essential. Excessively high initial prices risk limited coverage and slow uptake, while moderate pricing aligned with demonstrated value benefits patients and providers.
5. What is the outlook for biosimilars or generic versions of lecanemab?
Patent expirations could introduce biosimilars within 8-10 years, potentially reducing prices and expanding accessibility. However, such developments depend on patent protections and approval processes.
References
[1] Danyall, F. et al. (2023). FDA Approves Lecanemab for Alzheimer’s Disease. New England Journal of Medicine.
[2] MarketsandMarkets. (2022). Alzheimer's Disease Therapeutics Market Assessment.
[3] CMS Draft Coverage Guidelines. (2023). Medicare’s Coverage of Amyloid PET Imaging for Alzheimer’s.
[4] U.S. FDA. (2023). Lecanemab Highlights and Approval Details.
[5] Johnson, L. et al. (2023). Value-Based Pricing Strategies for Alzheimer’s Therapies. Health Affairs.
More… ↓
